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Broth microdilution MICs were determined for pairs of strains isolated from five AIDS patients with
polyclonal Mycobacterium avium infection. Four (80%) of the five patients were infected simultaneously with
strains having different antimicrobial susceptibility patterns. These findings have implications for the interpretation of susceptibility data in M. avium prophylaxis and treatment trials.
Organisms of the Mycobacterium avium complex (MAC) are
the most common cause of disseminated bacterial infection
among patients with AIDS in the United States (10). Assessment of MAC treatment regimens has been based on both
clinical and microbiologic responses, and attempts to correlate
pretreatment antimicrobial susceptibility profiles with outcome
have been made. These analyses have been complicated by the
lack of a consensus on an optimal method for susceptibility
testing of MAC. Various methods, including agar dilution,
broth dilution, and radiometric broth testing, have been reported (16). The radiometric BACTEC method has been proposed as a standard (13).
Most studies have been unable to correlate outcome of
MAC treatment with antibiotic susceptibility patterns (4, 14).
In one retrospective study of MAC pulmonary infection, responders were more likely than nonresponders to have received antibiotics to which their isolates were susceptible (9).
Two recent studies of AIDS patients with disseminated MAC
infection treated with clarithromycin provide the first suggestion that outcome correlates with antimicrobial susceptibility:
clinical and microbiologic responses were associated with clarithromycin MICs of #2 mg/ml, (2) and relapse was associated
with MICs of $8 mg/ml (3).
The existence of polyclonal infection among AIDS patients
with disseminated MAC infection is an additional factor which
may need to be considered when antimicrobial susceptibilities
are applied to treatment studies. Studies conducted by our
group using nonradiometric culture techniques and pulsedfield gel electrophoresis (PFGE) have shown that as many as
24% of AIDS patients with disseminated MAC infection have
polyclonal infection, that is, are infected simultaneously with
two different strains of M. avium (1a, 15). In the present study
we sought to determine whether different strains of M. avium
isolated simultaneously from the same patient had different
antimicrobial susceptibility patterns.
MAC was isolated from sputum, stool, bone marrow, liver,
and Isolator (Wampole Laboratories, Cranbury, N.J.) blood
cultures collected from human immunodeficiency virus-infected patients with CD4 counts of ,200/mm3 in Boston,
Mass., and New Hampshire. For each site with a positive cul-

ture, three distinct colonies were subcultured and analyzed by
PFGE according to previously published methods (1a, 15).
Patients were defined as having monoclonal M. avium infection
if all colonies from all positive body sites represented a single
strain as resolved by PFGE analysis and polyclonal infection if
the PFGE analysis resolved two or more distinct strains among
the isolates available (1a, 15). Subcultures of isolates were
characterized as transparent or opaque morphotypes (10). As
previously noted, cultures of different morphotypes could be
derived from the same strain (12) and had the same PFGE
pattern (1, 1a).
Stock antibiotic solutions were prepared according to the
manufacturer’s directions from powders of defined potency
and then diluted in water. Antibiotics from stock solutions
were distributed in 100-ml amounts in serial twofold dilutions
in sterile 96-well, round-bottom microtiter trays at two times
the final concentrations to be tested.
Isolates were tested by a modification of previously described broth microdilution methods (5, 11). Isolates from
frozen 7H9 broth stocks were plated as a confluent lawn on
Middlebrook 7H10 agar plates. Lawns were harvested after 3
to 5 days and suspended in normal saline with 0.5% Tween 80.
Single-cell suspensions were obtained by centrifugation at 50 3
g for 3 min. An aliquot of the supernatant was diluted with
normal saline to an optical density at 540 nm of 0.1, representing ;108 CFU/ml, as determined by plating serial 10-fold dilutions on 7H10 agar plates and determining colony counts
after 7 to 10 days. The bacterial suspension was diluted in 23
7H9 broth with Middlebrook ADC enrichment (Becton Dickinson Microbiology Systems, Cockeysville, Md.) to a concentration of ;1 3 105 CFU/ml, and 100 ml was distributed into
microtiter wells containing drug as described above to a final
inoculum of ;5 3 104 CFU/ml. The 7H9 broth used to test
clarithromycin and azithromycin was adjusted to pH 7.4 by
addition of sodium hydroxide. Plates were read after 10 to 12
days of incubation at 378C in an atmosphere containing 5%
CO2. Technicians reading the MIC results were not aware of
PFGE results. The MIC was defined as the lowest concentration of drug at which there was no significant visible growth.
Antibiotic susceptibility patterns were determined for each
strain: patterns were considered different if MICs of at least
two antimicrobial agents differed by .2 dilutions.
To determine reproducibility of MICs observed among different assays and among different colonial morphotypes of the

* Corresponding author. Mailing address: Infectious Disease Section, Dartmouth-Hitchcock Medical Center, 1 Medical Center Dr.,
Lebanon, NH 03756.
1008

VOL. 33, 1995

NOTES

1009

TABLE 1. MICs for paired isolates from five AIDS patients with polyclonal M. avium infection
MIC [mg/ml] (resistant MIC) (reference) of b:
Patientvisit no.

Sourcecolony no.a

1031-1c

Blood-1
Feces-3
Blood-2
Blood-3
Blood-1
Bone
Marrow-1
Blood-3
Feces-1
Liver-2
Liver-3

5026-1c
5029-3c
5060-1
1057-2

CLR
($8.0) (3)

AZI
($16.0) (7)

CF
($0.5) (13)

AMK
($8.0) (13)

EMB
($8.0) (13)

CIP
($4.0) (13)

SPA
($1.0) (17)

RBN
($0.5) (8)

2
0.12
4
#0.06
4
0.25

4
0.5
2
0.5
4
#0.25

#0.12
#0.12
0.5
0.25
0.5
#0.12

4
4
8
2
16
0.5

16
8
4
8
8
8

0.5
0.5
4
0.25
16
0.25

1
0.25
4
0.25
8
0.25

#0.06
#0.06
0.12
#0.06
0.5
#0.06

0.25
4
0.12
0.25

#0.25
2
0.5
0.5

#0.12
#0.12
#0.12
#0.12

4
4
4
4

4
16
4
4

1
1
0.25
0.5

1
1
0.25
0.5

#0.06
#0.06
#0.06
#0.06

a
For each patient, the two isolates represent different strains as determined by PFGE. Three colonies were selected from positive cultures from each body source
and are numbered 1 to 3. For all patients except 1057, transparent morphotypes of both strains were tested; for patient 1057, opaque morphotypes were tested for both
strains.
b
CLR, clarithromycin (Abbott Laboratories); AZI, azithromycin (Charles Pfizer, Inc.); CF, clofazimine (Ciba-Geigy Corp.); AMK, amikacin (Bristol Laboratories);
EMB, ethambutol (Lederle Laboratories); CIP, ciprofloxacin (Miles Laboratories); SPA, sparfloxacin (Parke-Davis); RBN, rifabutin (Adria Laboratories).
c
Received prior antimycobacterial therapy (1031 received INH, rifampin, and pyrazinamide; 5026 received rifampin, CF, EMB, AMK, and CIP; 5029 received CLR,
CLO, and EMB).

same strain, replicate determinations (median, 6; range, 2 to
16) were performed for seven strains from six patients. The
range of MICs observed was .2 dilutions for 0 (0%) of 140
antibiotic-strain combinations assayed by using opaque morphotypes and 6 (2.5%) of 244 combinations assayed by using
transparent morphotypes. For two strains, both transparent
and opaque morphotypes were tested. The range of MICs
observed was .2 dilutions for four of the eight antibiotics
tested for one strain and for three antibiotics with the other
strain. In each of these instances, the mean MICs for the
opaque morphotypes were lower than those for the transparent variants of the same strain.
Isolates were available from five AIDS patients with polyclonal infection. Three of the five patients were receiving multiple-drug antimycobacterial therapy at the time that cultures
demonstrated polyclonal infection. Antimicrobial susceptibilities were determined for five pairs of strains from the same
patient; for each pair, the same colonial morphotype was
tested for both strains (Table 1). For four of the five polyclonal
infections, the two infecting strains had different susceptibility
patterns as defined above. The observed MICs were compared
with resistance breakpoints suggested by other investigators (3,
7, 8, 13, 17). For each of the eight antimicrobial agents tested,
the number of patients simultaneously infected with one susceptible and one resistant isolate was as follows: clarithromycin
and azithromycin, each zero of five; rifabutin, one of five;
clofazimine, amikacin, ethambutol, and ciprofloxacin, each two
of five; and sparfloxacin, three of five. Each of the three patients who had received prior antimycobacterial therapy was
infected with one strain of M. avium that was resistant to one
or more antimicrobial agents to which the other strain was
susceptible.
We have demonstrated that AIDS patients with polyclonal
M. avium infection may be infected simultaneously with strains
that differ appreciably in their antimicrobial susceptibilities.
Such differences likely reflect the wide variability in susceptibility patterns found among random isolates of MAC (7). Of
potential significance, the differences between two infecting
strains were most apparent for strains from patients who were
receiving antimycobacterial treatment; susceptible and resistant strains of M. avium were present simultaneously in all
three such patients.

Polyclonal infections can be detected only by separately isolating and analyzing multiple individual colonies from a primary culture. Consequently, the multiple sensitivity patterns
identified in this study would not have been detected with
standard microdilution MIC or radiometric broth susceptibility
testing methods which are usually applied to subcultures derived from a single colony, a pool of three to five colonies, or
a broth (6, 13). If single colonies are used for susceptibility
testing, more-resistant coinfecting strains might be missed
completely. If a pool of colonies or a broth subculture is used
for susceptibility testing, the results may fail to reflect the most
resistant of multiple coinfecting strains. In view of the uncertainties associated with susceptibility testing for MAC infection
in general and for polyclonal MAC infection in particular, it is
difficult to recommend routine susceptibility testing of primary
clinical isolates at this time. Susceptibility testing should be
considered for MAC isolates associated with treatment or prophylaxis failure.
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